Sirigen Raises $6.1M for Technology Commercialization | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – UK amplification firm Sirigen today announced it has raised about £3.8 million ($6.1 million) in two completed rounds of financing, which it will use to support commercialization of its High Sensitivity Fluorescence technology.

Leading the rounds was a syndicate of new investors including IQ Capital, the National Endowment for Science, Technology, and the Arts, and YFM Private Equity. Existing investors Seraphim Capital and Oxford Capital Partners also participated.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Ivanka Trump and Secretary of Education Betsy DeVos call on girls to pursue STEM careers, the Associated Press reports.

Some science companies will be taking part in next month's March for Science, Fortune reports.

In Genome Research this week: longitudinal study of Burkholderia cenocepacia isolates from cystic fibrosis patients, long-read assembly approach, and more.

Shale oil companies are turning to DNA sequencing to find spots to drill, Reuters reports.